We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 11.50 | 0.70% | 1,651.00 | 1,651.00 | 1,652.00 | 1,656.00 | 1,637.00 | 1,650.50 | 4,661,376 | 16:35:08 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.80 | 68.01B |
From Apr 2019 to Apr 2024
By Oliver Griffin
GlaxoSmithKline PLC (GSK.LN) said Tuesday that new clinical data from a phase 3 trial has demonstrated high efficacy of Fluarix Tetra, an influenza vaccine for young children.
GSK said that Fluarix Tetra prevented influenza types A and B--acute, highly contagious, respiratory diseases caused by influenza viruses which are mainly spread through respiratory droplets.
The company said Fluarix Tetra demonstrated 63.2% vaccine efficacy against laboratory-confirmed moderate-to-severe influenza, and efficacy of 49.8% against influenza of any severity in children aged six months to 35 months.
In culture-confirmed influenza, Fluarix Tetra demonstrated vaccine efficacy of 77.6% in moderate-to-severe influenza, and efficacy of 60.1% against influenza of any severity, GSK said.
Write to Oliver Griffin at oliver.griffin@dowjones.com
(END) Dow Jones Newswires
March 06, 2018 06:49 ET (11:49 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
